Shared Care Protocol for the Management of Pseudomonas aeruginosa
Colonisation in Non-Cystic Fibrosis Adult patients with Bronchiectasis
(Off license Indication) click here & Proforma click here
Please access the NICE Summary of antimicrobial prescribing guidance - managing common infections via this link
Brand:Dificlir
Rationale:1,2
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
For further information in the Process for the prescribing and dispensing of Fidaxomicin in the management of Clostridium difficile click here
| Pack | Price |
|---|---|
| 20 tablet | £1,350.00 |
Only the licensed capsules are endorsed by Doncaster and Bassetlaw CCGs as the option for oral treatment. This is a safety measure to avoid incorrect dosing of the drug.
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
| Pack | Price |
|---|---|
| 28 capsule | £127.32 |
| Pack | Price |
|---|---|
| 28 capsule | £131.74 |
Pseudomonas aeruginosa colonisation in non-cystic fibrosis adult patients with bronchiectasis (Unlicensed indication)
Brand : Colomycin,
Use under Shared Care Protocol
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
| Pack | Price |
|---|---|
| 30 unit dose | £204.00 |
Hepatic encephalopathy
Brand: Targaxan 550mg
NICE TA337 Rifaximin for preventing episodes of overt hepatic encephalopathy
Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in people aged 18 years or older.
Rifamixin is licensed for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients aged 18 years or older. NICE guidance is based on 6-month trial data. A secondary care review will be undertaken at a maximum of six months following initiation. Continuation will be decided based on clinical efficacy.
The recommended dose is 550mg twice daily. The 200mg tablet (unlicensed) should not be prescribed.
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
| Pack | Price |
|---|---|
| 56 tablet | £259.23 |
Prevention of recurrence of Clostridium difficile infection (CDI)
Rationale 1,6
| Pack | Price |
|---|---|
| 1 vial |
Rationale 1
| Pack | Price |
|---|---|
| 1 vial |
| Pack | Price |
|---|---|
| 1 capsule | |
| 60 capsule | £377.00 |
Cystic fibrosis (Adjunct to standard antibacterial therapy)
Brand : Colomycin injection
NHS England Specialist Commissioning:
Prescribing to remain with specialist centre
April 2014
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
Pseudomonas aeruginosa colonisation in patients with cystic fibrosis (CF) aged 6 years and older.
Brand : Colobreathe dry powder inhaler device
Rationale 1,2
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
NHS England Specialist Commissioning:
Prescribing to remain with specialist centre
April 2014
NICE technology appraisal guidance 276
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Guidance
1.2 Colistimethate sodium DPI is recommended as an option for treating chronic pulmonary infection caused by P. aeruginosa in people with cystic fibrosis only if: they would clinically benefit from continued colistimethate sodium but do not tolerate it in its nebulised form and thus tobramycin therapy would otherwise be considered and the manufacturer provides colistimethate sodium DPI with the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS.
1.3 People currently using tobramycin DPI or colistimethate sodium DPI that is not recommended according to 1.1 or 1.2 should be able to continue treatment until they and their clinician consider it appropriate to stop. For children and young people this decision should be made jointly by the clinician, the child or young person and their parents or carers.
Issued: March 2013
Further information: http://www.nice.org.uk/nicemedia/live/14134/63269/63269.pdf
Staphylococcus aureus bacteremia in cases when associated with RIE or with complicated skin and soft-tissue infections due to known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infection and on the advice of local microbiologists or specialists in infectious disease.
Brand: Cubicin
Rationale: 1,2
Daptomycin: risk of eosinophilic pneumonia
MHRA Drug safety update Volume 4 Issue 7 February 2011
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
Infection - all licensed indications
Brand: Fomicyt
Rationale: 1,2
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
Oxazolidinone antibacterial to be initiated under specialist supervision and reserved for infections resistant to other antibacterials or when they are not tolerated
Rationale: 1,2,3
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
Atypical pneumonias
Brand: Pentacarinat
Rationale 1,2
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
Diarrhoea - travellers
Brand: Xifaxanta 200mg tab
Rationale: 1
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
Nosocomial pneumonia
Brands: Vibativ
Rationale: 1,2
Drug Safety Update
Recommendations for use and important risks (nephrotoxicity, QTc prolongation, reproductive toxicity and off-label use) - Sent by Clinigen, click here
Nov 2014
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections